CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ExposureWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug605 ColdZyme® mouth spray Wiki 0.71
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003139 Common Cold NIH 0.50
D007239 Infection NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Gut Microbiota, "Spark and Flame" of COVID-19 Disease

Elderly, hypertension, diabetes and cardiovascular diseases are risk factors for COVID-19 morbility and mortality. However, the real reason for this is not yet understood. It is well documented that gut microbiota has a critical role in health, particularly in the immune system and therefore, we propose that gut microbiota composition could affect vulnerability and disease outcomes of COVID-19.

NCT04355741 COVID-19 Other: Exposure

Primary Outcomes

Measure: Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.

Time: Stool samples of COVID-19 patients will be collected after subject enrollment (single point collection)

Secondary Outcomes

Measure: Differences in gut microbiota composition between COVID-19 patients in relation to mortality.

Time: Through study completion, an average of 3 months.

Measure: Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.

Time: Through study completion, an average of 3 months.

Measure: Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.

Time: Through study completion, an average of 3 months.

2 VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity

Vitamin D deficiency has been linked to hypertension, autoimmune, infectious and cardiovascular diseases which are risk factors for COVID-19. Moreover, COVID-19 patients have a very high prevalence of hypovitaminosis D (Turin data). Taken together, we aim to investigate whether genetic variants in vitamin D-related genes contribute to a poor COVID-19 outcome, particularly in hypertension and CV patients, proposing thus a personalized therapeutics based on vitamin D supplementation in order to reduce the severity and deaths.

NCT04370808 COVID-19 Other: Exposure
MeSH:Infection

Primary Outcomes

Measure: Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.

Time: Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).

Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.

Time: Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).

Secondary Outcomes

Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.

Time: Through study completion, an average of 3 months.

Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.

Time: Through study completion, an average of 3 months.

Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.

Time: Through study completion, an average of 3 months.

Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.

Time: Through study completion, an average of 3 months.

Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.

Time: Through study completion, an average of 1 year.

Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.

Time: Through study completion, an average of 3 months.


No related HPO nodes (Using clinical trials)